Since enlarged lymph nodes, as CLL major proliferation sites, are an important clinical indicator of progression, we next investigated BCR-mediated CXCR4 downregulation capacity in patients presenting or not with lymphadenopathy (Table 1). This evidence concerns the gene CXCR4 and B-cell chronic lymphocytic leukemia.